Gain Therapeutics (NASDAQ:GANX – Get Free Report) and Larimar Therapeutics (NASDAQ:LRMR – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, institutional ownership, earnings and profitability.
Earnings and Valuation
This table compares Gain Therapeutics and Larimar Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Gain Therapeutics | $50,000.00 | 1,646.09 | -$20.41 million | ($0.61) | -3.51 |
| Larimar Therapeutics | N/A | N/A | -$80.60 million | ($1.93) | -1.68 |
Profitability
This table compares Gain Therapeutics and Larimar Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Gain Therapeutics | N/A | -341.32% | -174.09% |
| Larimar Therapeutics | N/A | -91.83% | -74.60% |
Insider & Institutional Ownership
12.0% of Gain Therapeutics shares are held by institutional investors. Comparatively, 91.9% of Larimar Therapeutics shares are held by institutional investors. 7.2% of Gain Therapeutics shares are held by company insiders. Comparatively, 4.5% of Larimar Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Risk and Volatility
Gain Therapeutics has a beta of 0.06, meaning that its stock price is 94% less volatile than the S&P 500. Comparatively, Larimar Therapeutics has a beta of 1.06, meaning that its stock price is 6% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent ratings for Gain Therapeutics and Larimar Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Gain Therapeutics | 1 | 0 | 6 | 0 | 2.71 |
| Larimar Therapeutics | 1 | 0 | 8 | 1 | 2.90 |
Gain Therapeutics currently has a consensus price target of $8.67, suggesting a potential upside of 304.98%. Larimar Therapeutics has a consensus price target of $16.71, suggesting a potential upside of 414.29%. Given Larimar Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Larimar Therapeutics is more favorable than Gain Therapeutics.
Summary
Larimar Therapeutics beats Gain Therapeutics on 9 of the 13 factors compared between the two stocks.
About Gain Therapeutics
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.
About Larimar Therapeutics
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.
Receive News & Ratings for Gain Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gain Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
